AlphaStocks
6.2
Consider Buy

Biogen Inc. (BIIB)

As of Sep 20, 2026, Biogen Inc. (BIIB) scores 6.2/10 on AlphaStocks' five-model composite, #43 of 168 Health Care stocks. At $216, BIIB trades 22% below its model fair value of $278.

Health Care / Biotechnology

S&P 500

$215.71

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#43out of 168 in Health Care

Is BIOGEN INC. a Good Investment in 2026?

BIOGEN INC. (BIIB) scores 6.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates BIOGEN INC. as Attractive (5/9). The Lynch model is the least favorable, rating it Neutral. BIOGEN INC. currently trades 22% below its estimated fair value of $278. BIOGEN INC. ranks #43 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E24.5ROE-651.7Market Cap32B

Estimated Fair Value

$278.0922% below

Trading below estimated fair value. P/E of 25x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

PEG 2.1 · Stalwart

Greenblatt

Attractive

Earnings yield 5.7% · ROC 21%

Frequently Asked Questions

Is BIOGEN INC. (BIIB) a good investment?
As of Sep 20, 2026, Biogen Inc. (BIIB) scores 6.2/10 on AlphaStocks' five-model composite, #43 of 168 Health Care stocks. At $216, BIIB trades 22% below its model fair value of $278. That is a middle-of-the-pack score with no strong signal either way.
What is BIOGEN INC.'s Piotroski F-Score?
BIOGEN INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BIIB overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $278, BIIB appears undervalued. The stock currently trades 22% below its estimated fair value. Trading below estimated fair value. P/E of 25x is moderate for this quality level.
How does BIIB compare to other Health Care stocks?
BIOGEN INC. ranks #43 out of 168 stocks in the Health Care sector, placing it in the top 26% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about BIIB?
AlphaStocks evaluates BIIB using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.2/10.

Similar Stocks

ABBVINCYHRMY

Compare BIIB with

ABBV vs BIIBBIIB vs INCYBIIB vs HRMYBIIB vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer